Pancreatitis is the most common adverse event of endoscopic retrograde cholangiopancreatography, with the potential for clinically significant morbidity and mortality. Several patient and procedural risk factors have been identified that increase the risk of posteendoscopic retrograde cholangiopancreatography pancreatitis (PEP). Considerable research efforts have identified several pharmacologic and procedural interventions that can drastically affect the incidence of PEP. This review article addresses the underlying mechanisms at play for the development of PEP, identifying patient and procedural risk factors and meaningful use of riskstratification information, and details current interventions aimed at reducing the risk of this complication. 1-4 Several large clinical studies have reported the incidence of post-ERCP pancreatitis (PEP) to be 3% to 5%. 5, 6 A recent meta-analysis composed of 21 prospective studies found the incidence of PEP to be consistent with previously described studies at approximately 3.5% 7 ; however, PEP rates ranged from 1% to nearly 16% depending on patient selection. 6, 8 There are several patient-and procedure-related factors that have been identified to increase the risk of PEP. The presence of multiple factors can have a cumulative effect. As a result, several chemical and procedural interventions have been studied in the hopes of decreasing PEP rates. Herein, we describe the potential mechanisms of pancreatic injury during ERCP, review patientand procedure-related risk factors, and discuss the latest studies involving pharmacologic and procedural interventions aimed at reducing the rates of PEP.
P
ancreatitis remains the most common adverse event of endoscopic retrograde cholangiopancreatography (ERCP), with the potential for substantial morbidity and mortality. [1] [2] [3] [4] Several large clinical studies have reported the incidence of post-ERCP pancreatitis (PEP) to be 3% to 5%. 5, 6 A recent meta-analysis composed of 21 prospective studies found the incidence of PEP to be consistent with previously described studies at approximately 3.5% 7 ; however, PEP rates ranged from 1% to nearly 16% depending on patient selection. 6, 8 There are several patient-and procedure-related factors that have been identified to increase the risk of PEP. The presence of multiple factors can have a cumulative effect. As a result, several chemical and procedural interventions have been studied in the hopes of decreasing PEP rates. Herein, we describe the potential mechanisms of pancreatic injury during ERCP, review patientand procedure-related risk factors, and discuss the latest studies involving pharmacologic and procedural interventions aimed at reducing the rates of PEP.
MECHANISMS OF PEP
There are several potential underlying mechanisms of pancreatic injury during ERCP, including mechanical, thermal, chemical, hydrostatic, enzymatic, and microbiologic insults. 9 Prolonged manipulation of the papillary orifice, difficult cannulation of the biliary tree, and repeated inadvertent instrumentation of the pancreatic duct result in ductal injury or injury to the ampulla. [10] [11] [12] Thermal injury may result from electrocautery current used during sphincterotomy (biliary or pancreatic), endoscopic papillectomy, or ablation of neoplastic lesions in the region of the ampulla of Vater. 13, 14 Resultant papillary edema caused by mechanical or thermal injury is thought to obstruct the outflow of pancreatic secretion, resulting in pancreatitis. Contrast agents could potentially lead to PEP by causing chemical injury; however, the data remain controversial. 15 George et al 15 performed a meta-analysis to determine whether the osmolality of contrast media used affects the incidence of PEP. Thirteen randomized controlled trials (RCTs) were included comparing the incidence of PEP (defined as pancreatic enzyme levels elevated 3 times above their upper limits of normal [ULNs] and typical pancreatic pain) with the use of high-vs lowosmolality contrast media. Using logistic regression, they found no significant difference in PEP rates between low-and high-osmolality contrast media. Hydrostatic injury, which results from overinjection of the pancreatic duct or infusion of water or saline through manometry catheters, is thought to be one of the most important causes of PEP. 14, 16 Introduction of foreign material into the pancreatic duct results in the intraluminal activation of proteolytic enzymes, which subsequently results in enzymatic injury. In addition, the reflux pathogenesis describes the introduction of intestinal enzymes into the pancreatic ductal tree by ERCP. 17 It is thought that contrast agents, not currently used in clinical practice, may activate intracellular trypsin, with resultant PEP. Last, bacterial translocation and subsequent activation of the inflammatory cascade is also thought to contribute to the pathogenesis of PEP. 18 These underlying mechanisms may work independently or in concert, resulting in a cascade of events that activate proteolytic enzymes, promote autodigestion, and impair acinar secretion, with subsequent clinical manifestations of the local and systemic effects of pancreatitis. [19] [20] [21] Therefore, most preventive therapies are aimed at interrupting various triggers of this cascade.
RISK FACTORS AND MEANINGFUL USE OF RISK-STRATIFICATION INFORMATION
Several studies have identified factors that increase the risk of PEP, which can be divided into patient-and procedure-related factors. Table 1 3,22-26 summarizes expert consensus, based on several clinical trials, of independent risk factors for PEP. There are several other factors that have been suggested to be possible risk factors for PEP but that have not yet been universally accepted as independent risk factors, including self-expanding metal stent placement, 27 pancreatic deep wire passage, 28 and intraductal papillary mucinous neoplasm. 26 These risk factors seem to have a synergistic effect, as evidenced by Freeman et al, 9 who found the risk of PEP in a young woman with clinical suspicion of sphincter of Oddi dysfunction, a normal bilirubin level, and difficulty with cannulation to be in excess of 40%. This particular subset of patients (women with suspected sphincter of Oddi dysfunction) not only is at an increased risk for PEP but also seems to develop more severe PEP, and studies have found there to be a higher mortality rate as well. 1, 9, 29 In addition, the individual endoscopist's procedure volume and level of training have been implicated as independent risk factors for PEP. A study by Loperfido et al 30 evaluated the adverse events of diagnostic and therapeutic ERCP in 2769 patients at medical centers in Italy during a 2-year period. Of the 9 centers, 6 were considered to be small because they performed ERCP on fewer than 200 patients annually. Low volume was identified as an independent risk factor for overall major adverse events of therapeutic ERCP, which supported a policy of centralization of ERCP in referral centers to limit potential adverse events. Other multicenter studies, however, have not confirmed this trend, which is thought to be due to the fact that low-volume endoscopists have a tendency to perform lower-risk procedures.
1,9,31 Nevertheless, we recommend that high-risk cases (based on patient-related risk factors or anticipated high-risk procedural interventions) be referred to tertiary and quaternary medical centers, where a high-volume endoscopist can perform the procedure.
Thus, it is imperative for the endoscopist to understand the aforementioned risk factors and incorporate them into clinical decision making. The clinical endoscopist can gauge the risk, in part, of PEP based on nonmodifiable patient-related risk factors. This allows for appropriate case selection and improved patient relations regarding discussing the risk-benefit ratio of the procedure. In addition, combining procedure-and patient-related risk factors allows for global assessment of a patient's overall risk of PEP, which could help further guide management (ie, postprocedural hospital admission for further observation in a patient deemed to be at high risk for PEP).
DIAGNOSIS, SEVERITY, AND MANAGEMENT OF POST-ERCP PANCREATITIS
To date, there are no standardized diagnostic criteria for PEP; however, the consensus guidelines proposed by Cotton et al 32 are the
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d The development of posteendoscopic retrograde cholangiopancreatography pancreatitis (PEP) is thought to be multifactorial, including mechanical, thermal, chemical, hydrostatic, enzymatic, and microbiologic insults. Thus, chemoprophylaxis and procedural techniques to prevent PEP should take all these factors into account.
d The risk of PEP in low-and high-risk patients is greater than 5% and 16%, respectively. To minimize this risk, clinicians must choose appropriate patients, use endoscopic retrograde cholangiopancreatography pancreatitis almost exclusively as a therapeutic procedure, use sound procedural techniques, and consider the administration of rectal indomethacin, the use of aggressive hydration, or the placement of pancreatic stents.
d Large randomized controlled trials are necessary to further define which patient populations derive benefit from rectal indomethacin therapy and to define the role of pancreatic duct stent placement in low-risk patients.
most generally used. Per Cotton et al, 32 the diagnosis of PEP is defined as the presence of pancreatitis (new pancreatic-type abdominal pain accompanied by at least a threefold increase in the serum amylase level) that has developed de novo 24 hours after ERCP. If the diagnosis of PEP remains in doubt, contrast-enhanced computed tomography (CT) of the abdomen or magnetic resonance imaging (if renal function precludes CT) should be performed to make the diagnosis. However, a normal CT finding does not exclude mild pancreatitis.
Early diagnosis of PEP may be possible by evaluating serum amylase or lipase levels within 6 hours of the procedure. [33] [34] [35] Ito et al 33 evaluated the relationship between the change in serum amylase levels and PEP. Serum amylase concentrations were measured before and 3, 6, and 24 hours after the procedure in 1291 ERCP-related procedures. Forty-seven patients (3.6%) developed PEP. Subgroup analysis revealed that 3 hours after the procedure, 1% of patients with normal serum amylase levels and 1%, 5%, 20%, 31%, and 39% of patients with amylase levels elevated 1 to 2ÂULN, 2 to 3ÂULN, 3 to 5ÂULN, 5 to 10ÂULN, and more than 10ÂULN developed PEP, respectively. Of 143 patients with elevated serum amylase levels 3 hours after the procedure that remained elevated 6 hours after the procedure, 37 (25.9%) developed PEP. Conversely, of 45 patients with elevated serum amylase levels 3 hours after the procedure (>2ÂULN) with subsequent decrease of serum amylase concentrations 6 hours after the procedure, only 4 (8.9%) developed PEP. This led to the conclusion that PEP is associated with an increase in serum amylase concentrations greater than 2ÂULN 3 hours after the procedure with sustained elevation 6 hours after the procedure and that a decrease in amylase levels 6 hours after the procedure suggests a decreased likelihood of developing PEP.
The severity of PEP is mainly based on the length of hospitalization, as illustrated in Table 2 . 32 Because the management of PEP is similar to that of other causes of acute pancreatitis, the same prognostic indicators apply to PEP as to other causes of acute pancreatitis. Several scoring systems have been validated in predicting the severity of pancreatitis, including the bedside index for severity in acute pancreatitis (BISAP), 36 Acute Physiology and Chronic Health Examination II score, 37 Ranson criteria, 38 Balthazar score (or CT severity index), 39 and Glasgow criteria. 40 Papachristou et al 36 compared BISAP with the other traditional multifactorial scoring systems and found it to have similar test performance characteristics for predicting mortality with clinically relevant and easily obtainable components. Table 3 36 outlines the BISAP scoring system. The downside to the currently available predicting models is that it has not been validated for predicting outcomes such as length of hospital stay, need for intensive care unit care, or need for intervention.
The initial management of a patient with PEP centers on supportive care with aggressive fluid resuscitation, pain control, and nutritional support. Acute pancreatitis typically results in significant intravascular loss; therefore, aggressive intravenous hydration should be at least 250 to 300 mL/h (in the absence of concomitant cardiac or renal comorbidities). Hydration should be adjusted based on clinical assessment and titrated to hematocrit and blood urea nitrogen values. 41 As with other cases of acute pancreatitis, pain control, nutritional support, and monitoring for infection are paramount. Details regarding the management and complications of acute pancreatitis are beyond the scope of this article but are discussed in depth elsewhere. 37, 41 PREVENTION OF PEP Pharmacologic Agents During the past 3 decades, nearly 100 RCTs have aimed to identify potential pharmacologic agents to use for the chemoprevention of PEP, with largely disappointing results. The ideal pharmacologic agent should be short-acting, well-tolerated with a low adverse effect profile, and, most importantly, highly efficacious in reducing PEP. Thus far, clinical trials have had inadequate sample sizes and negative, conflicting, or inconclusive results. In addition, the promise of a previous positive meta-analysis of agents 42 that were subsequently disproved by further clinical investigation 43 further amplifies the pessimism surrounding PEP chemoprevention.
Nonsteroidal Anti-inflammatory Drugs
To date, clinical data supporting the use of nonsteroidal anti-inflammatory drugs (NSAIDs) for PEP have renewed hope in chemoprevention. The NSAIDs inhibit several mediators of the inflammatory cascade that are thought to play a role in the pathogenesis of acute pancreatitis, namely, prostaglandins and phospholipase A-2. 44 Initial data from 2003-2008 evaluating the chemoprotective effects of NSAIDs (single-dose rectal indomethacin or diclofenac) reported conflicting, albeit encouraging, results. [45] [46] [47] A subsequent meta-analysis by Elmunzer et al, 48 which totaled 912 patients, found that patients who received NSAIDs in the periprocedural period were 64% less likely to develop pancreatitis and 90% less likely to develop moderate to severe pancreatitis. The pooled analysis found a number needed to treat (NNT) to prevent 1 episode of pancreatitis of 15. In addition, there were no adverse events attributed to NSAID therapy in any of the clinical trials included. Despite the overwhelmingly positive results of this meta-analysis, there was not a push for NSAID use in PEP prevention.
This sparked a large-scale, multicenter RCT by Elmunzer et al 49 totaling 602 patients randomized to receive single-dose rectal indomethacin or placebo immediately after ERCP. The rates of PEP in NSAID-treated patients and placebotreated patients were 9.2% and 16.9%, respectively (P¼.005). The rates of moderate to severe pancreatitis in NSAID-treated patients and placebo-treated patients were 4.4% and 8.8%, respectively (P¼.03). Last, the use of rectal indomethacin was associated with a 7.7% absolute risk reduction (NNT¼13) and a 46% relative risk reduction in PEP (P¼.005), which led the investigators to conclude that rectal indomethacin therapy significantly reduces the incidence of PEP in high-risk patients. Subsequent metaanalyses have reaffirmed these findings, [50] [51] [52] and, thus, the use of 100 mg of rectal indomethacin or diclofenac has become the standard of care in all high-risk patients. 53 A recent publication has cast a doubt on the utility of NSAIDs for the prevention of PEP. 54 Levenick et al 54 performed a singlecenter, prospective, double-blind, placebocontrolled trial evaluating the efficacy of prophylactic indomethacin use for all patients undergoing ERCP, including those at average risk for PEP. The trial included 449 consecutive patients who underwent ERCP from March 1, 2013, through December 31, 2014, with approximately 70% of the cohort at average risk for PEP. During the procedure, participants were randomized in a 1:1 manner to receive either a single dose of 100 mg of indomethacin rectally (n¼223) or a placebo suppository (n¼226), with the development of PEP as the primary end point (defined as new upper abdominal pain, 3ÂULN elevation of lipase levels, and hospitalization after ERCP for 2 consecutive nights). Sixteen patients 49 First and foremost, the patient population in the multicenter trial 49 greatly differed from that in the single-center study by Levenick et al. 54 Most patients in the trial by Elmunzer et al were women with a clinical suspicion of sphincter of Oddi dysfunction, a subset of patients who are, by definition, at high-risk for PEP. 49 In contrast, there was a relatively even split between female and male patients in the trial by Levenick et al, 54 with relatively few patients suspected of having sphincter of Oddi dysfunction (14 of 449 patients). Second, the number of patients who received prophylactic duct stents was substantially higher in the trial by Elmunzer et al 49 (w80% of all patients) compared with the trial by Levenick et al 54 (w15% of all patients). Coupled, these 2 factors might account for the different outcomes seen in the 2 trials.
Protease Inhibitors
The activation and propagation of proteases, namely, trypsin, is one of the inciting events in the development of acute pancreatitis. 17 Protease inhibitors prevent the activation of trypsin, and, thus, several synthetic protease inhibitors have been studied in the prevention of PEP, namely, gabexate, ulinastatin, and nafamostat mesylate.
Manes et al 55 performed a multicenter, prospective RCT evaluating the use of gabexate mesylate in 608 patients (group A ¼ 500 mg within 1 hour before ERCP [n¼203], group B ¼ 500 mg within 1 hour after ERCP [n¼203], or group C ¼ saline solution [n¼202]) to evaluate its efficacy on the incidence of PEP. They found the incidence of pancreatitis to be 3.9%, 3.4%, and 9.4% in groups A, B, and C, respectively (P<.01). Thus, the investigators suggested administering gabexate mesylate after ERCP in patients recognized to be at high risk for PEP. A similar study by Xiong et al 56 found a significant reduction in the incidence of PEP in patients pretreated with gabexate mesylate (continuous intravenous infusion of 300 mg of gabexate mesylate dissolved in 500 mL of Ringer solution [n¼97] at 111 mL/h, starting 30 minutes before the procedure and continuing for up to 4 hours after the procedure) compared with placebo (n¼96) (3.1% vs 10.5%, respectively; P¼.04). The results suggested that a 4.5-hour infusion of gabexate mesylate could prevent PEP. 56 Conversely, 2 separate large, multicenter RCTs by Andriulli et al evaluating the efficacy of short-term (totaling 2.5 hours, starting 30 minutes before the procedure and continuing for up to 2 hours after the procedure) 57 and long-term (totaling 6.5 hours, starting 30 minutes before the procedure and continuing for up to 6 hours after the procedure) 58 administration of gabexate mesylate found gabexate mesylate to be ineffective in reducing the incidence of PEP compared with placebo. The heterogeneity present in the available studies led to a subsequent meta-analysis of 5 high-quality studies. 43 The rates of PEP in patients treated with gabexate mesylate and controls were 4.8% and 5.7%, respectively (P¼.34). In addition, the pooled data produced no significant effect for either short-term (<6 hours) or long-term (>12 hours) administration of gabexate mesylate.
One of the major pitfalls to gabexate mesylate use is its extremely short half-life, hence the need for prolonged infusions over several hours. 59 Ulinastatin and nafamostat mesylate are 2 synthetic protease inhibitors that offer a longer half-life than gabexate mesylate. Ulinastatin has a half-life of approximately 33 minutes and, as a result, can be given as a bolus injection. 60 Tsujino et al 61 evaluated the efficacy of ulinastatin for the prevention of PEP in a large, multicenter RCT where 406 patients were randomized to receive ulinastatin (n¼204) (150,000-U intravenous infusion for 10 minutes immediately before ERCP) or placebo (n¼202). The rate of PEP in patients who received ulinastatin vs placebo was 2.9% vs 7.4% (P¼.041). There were no reported adverse effects related to the medication in the ulinastatin group, which led the investigators to conclude that short-term administration of ulinastatin decreases the overall incidence of PEP. A subsequent study by Yoo et al 62 randomized 227 patients, identified during ERCP to be at high risk for PEP, to receive either ulinastatin (n¼119) (100,000 U) or placebo (n¼108) immediately after the procedure. They found there to be no significant differences between the ulinastatintreated and placebo cohorts (rates of pancreatitis were 5.6% and 6.7%, respectively), which led the investigators to conclude that low-dose treatment with ulinastatin immediately after ERCP did not influence the incidence of PEP in high-risk patients. This study was included in a meta-analysis that totaled 7 RCTs comparing ulinastatin with placebo (n¼5) and ulinastatin with gabexate mesylate (n¼2). 63 This meta-analysis found that ulinastatin reduced the incidence of PEP (odds ratio [OR]¼0.53; 95% CI, 0.31-0.89; P¼.02); however, subsequent sensitivity and subgroup analyses did pool conflicting results. This led the investigators to conclude that ulinastatin shows some promise in preventing PEP for patients at average risk when given intravenously at a dose of 150,000 U or greater just before ERCP.
Nafamostat mesylate has a half-life nearly 20 times longer and a potency up to 100 times greater than gabexate mesylate. 64 Three RCTs, to date, have evaluated the use of nafamostat mesylate in decreasing the incidence of PEP. [65] [66] [67] The first comes from Choi et al, 65 whose large single-center RCT randomized 704 patients to receive nafamostat mesylate (n¼354) (20 mg of nafamostat mesylate in 500 mL of 5% dextrose solution) or placebo (n¼350). There was a significant difference in the incidence of PEP in the nafamostat mesylateetreated cohort compared with the placebo group (3.3% vs 7.4%, respectively; P¼.004). A prospective RCT by Yoo et al 66 reported the benefit of nafamostat mesylate in reducing the incidence of PEP. Last, Park et al 67 evaluated the use of highdose nafamostat mesylate (50 mg), with high-risk patients in mind, in decreasing the incidence of PEP. A total of 608 patients were randomized to receive an infusion of 20 mg of nafamostat mesylate, 50 mg of nafamostat mesylate, or placebo; they found a significant difference in the incidence of PEP with or without nafamostat mesylate (4.0% vs 5.1% vs 13.0%, respectively; P<.001). Subgroup analysis revealed that the rate of PEP was significantly different in low-risk patients receiving nafamostat mesylate compared with controls; however, this was not seen in high-risk patients.
Although protease inhibitors have shown some promise, they are costly, require extremely high NNTs to prevent a single episode of PEP (gabexate ¼ 33 and ulinastatin ¼ 29), 68 and possibly necessitate hospital admission for medication infusion, all of which may preclude their mainstream use.
Somatostatin and Octreotide
Somatostatin is a natural hormone that potently inhibits the pancreatic exocrine secretion, which is thought to play a pivotal role in the pathogenesis of acute pancreatitis by causing autodigestion of the organ. 69 A meta-analysis by Andriulli et al 43 included 9 high-quality trials evaluating the effect of somatostatin on the incidence of PEP. Pooled data found there to be no significant effect of somatostatin on the development of PEP (7.3% of controls vs 5.3% of treated patients; OR¼0.73; 95% CI, 0.54-1.006), irrespective of length of somatostatin infusion (short, <6 hours; long, !12 hours). A meta-analysis by Rudin et al 70 ( 7 RCTs including 3130 patients), however, reported conflicting results: they found there to be a significant reduction of PEP with long-term somatostatin infusion (defined as !12 hours).
Octreotide is a synthetic analogue of somatostatin with a longer half-life. A metaanalysis by Andriulli et al, 42 which included 10 studies, found there to be no effect of octreotide on the development of PEP. Subsequent RCTs have also reported conflicting results. 71, 72 Thomopoulos et al 71 evaluated whether an increased dosage of octreotide would reduce the incidence of PEP. This RCT randomized 201 patients to receive 500 mg of octreotide (n¼100), given 3 times daily subcutaneously starting 24 hours before ERCP, or placebo (n¼101). They found the incidence of PEP to be significantly lower in the octreotide-treated group compared with the placebo group (2.0% vs 8.9%, respectively; P¼.03), which led the investigators to support the use of 24-hour prophylaxis with high-dose octreotide in PEP prevention. Conversely, a multicenter RCT by Testoni et al, 72 which randomized 114 patients to receive 200 mg of octreotide (n¼58), given 3 times daily subcutaneously starting 24 hours before ERCP, or placebo (n¼56), found there to be no significant difference in the rates of PEP (12.0% vs 14.3%, respectively) or in the severity of pancreatitis, which led the investigators to conclude that 24-hour prophylaxis with octreotide is ineffective in preventing PEP. A subsequent metaanalysis by Zhang et al, 73 which included 18 RCTs, examined the effects of octreotide at different dosages on PEP. They used a dose of 500 mg as their cutoff value, and the rate of PEP was analyzed using a fixed effects model. They found that at doses of 500 mg or greater, there was a significant difference in the incidence of PEP (3.4% in the octreotide-treated group vs 7.5% in the control group; pooled OR¼0.45; 95% CI, 0.28-0.73; P¼.001, NNT¼25). In patients treated with a dose less than 500 mg, there was no difference in the rates of PEP, which led the authors to conclude that octreotide is effective in preventing PEP, but only at sufficient doses (ie, !500 mg).
Although octreotide shows promise, the optimal timing and dosage of administration remains an area for further study. Current guidelines do not recommend octreotide for the prophylaxis of PEP but state that future studies should evaluate its efficacy at dosages of 500 mg or greater. 53 
Nitroglycerin
Nitroglycerin is a smooth muscle relaxant thought to promote pancreatic blood flow and decrease sphincter of Oddi pressures. 74 To date, there has been conflicting data regarding the use of nitroglycerin, with 3 placebocontrolled RCTs reporting a significant reduction in the incidence of PEP [75] [76] [77] and 4 reporting no benefit. [78] [79] [80] [81] Recently, however, Sotoudehmanesh et al evaluated combination therapy with rectal indomethacin and sublingual nitrates in the prevention of PEP, with patients at high risk for PEP in mind (>80%). 82 In this double-blind RCT, 300 patients were randomized to receive 100 mg of rectal indomethacin plus 5 mg of sublingual nitrate, or 100 mg of rectal indomethacin plus sublingual placebo before ERCP. They found the rates of PEP to be significantly decreased in patients who received combination indomethacinnitroglycerin therapy compared with the indomethacin-placebo cohort (6.7% vs 15.3%, respectively; P¼.02). Note that a substantial portion of the study sample did not receive a pancreatic duct stent. They concluded that combination therapy with rectal indomethacin and sublingual nitrates before ERCP was significantly more likely to reduce the incidence of PEP compared with rectal indomethacin therapy alone. Nitrates have not yet made their way into guidelines 53 ; however, they should be considered as adjunctive therapy to rectal NSAIDs in high-risk patients who do not receive a prophylactic pancreatic duct stent. Further larger-scale, multicenter RCTs are necessary to establish the role of nitrates in decreasing the incidence of PEP.
Allopurinol and N-acetylcysteine Capillary endothelial injury, mediated by oxygen-derived free radicals, is thought to play a pivotal role in the pathogenesis of acute pancreatitis. 83 Xanthine oxidase is thought to generate oxygen-derived free radicals via catalyzing the conversion of hypoxanthine to xanthine. Allopurinol, a xanthine oxidase inhibitor, is postulated to mediate this pathway, thus reducing the incidence of PEP. However, the early success of canine models 84 did not translate into human studies, which had conflicting results. [85] [86] [87] [88] A pooled meta-analysis by Zheng et al, 89 which included 6 RCTs totaling 1554 patients, evaluated the efficiency of allopurinol in the prevention of PEP. The ORs for allopurinol were 0.74 (95% CI, 0.37-1.48; P¼.40) for PEP and 0.88 (95% CI, 0.37-2.11; P¼.78) for severe PEP, which led the authors to conclude that allopurinol cannot prevent the incidence of PEP and thus not to recommend its use in the prophylaxis of PEP.
N-acetylcysteine is a free radical scavenger, which has shown benefit in chemical-induced pancreatitis in mouse models. 90 However, this benefit did not translate to human studies. 91, 92 Katsinelos et al 91 evaluated the efficacy of intravenous N-acetylcysteine for the prevention of PEP by randomizing 256 patients to receive intravenous N-acetylcysteine (70 mg/kg 2 hours before ERCP and 35 mg/kg at 4-hour intervals for 24 hours after the procedure) or placebo with normal saline. The incidence of PEP was 12.1% in the N-acetylcysteine group and 9.6% in the placebo group, which led the authors to conclude that there was no beneficial effect of N-acetylcysteine on the incidence and severity of PEP. A subsequent study by Milewski et al 92 evaluated the effect of N-acetylcysteine on the incidence of PEP by randomizing 106 patients to receive N-acetylcysteine (n¼55) (two 600-mg doses orally 24 and 12 hours before ERCP and 600 mg intravenously, twice a day for 2 days after ERCP) or placebo with isotonic saline (n¼51). They found no significant difference in the rate of PEP between the 2 groups, which led to the conclusion that the use of N-acetylcysteine has no chemoprotective effect against PEP.
Procedural Techniques
Many of the procedure-related risk factors described previously herein, although predisposing to PEP, are often unavoidable. Therefore, methodical and precise technical practices are a must during ERCP to minimize the risk of PEP.
Biliary Access
As previously described, difficult cannulation and pancreatic duct injection are independent procedure-related risk factors for PEP. As such, selective cannulation of the common bile duct (CBD) via insertion of a guidewire and limited injection of contrast into the pancreatic duct are likely to decrease the risk of PEP.
Normally, a guidewire with a hydrophilic tip (either 0.032 or 0.025 inches in diameter) is preloaded into a papillotome. The papillotome is then oriented such that it is in the 11-o'clock position on the papilla, and flexed in the presumed axis of the bile duct. The direct contact method refers to minimal insertion (approximately 2-3 mm) of the papillotome into the ampulla with subsequent passage of the guidewire, under fluoroscopic guidance, through the CBD until it is seen to enter the bile duct. If at this point the pancreatic duct is cannulated, the guidewire can simply be withdrawn and repositioned in an attempt to cannulate the CBD. A recent meta-analysis by Tse et al, 93 composed of 12 RCTs and totaling 3450 participants, evaluated the effectiveness and safety of the guidewire-assisted cannulation technique compared with conventional contrast-assisted cannulation for the prevention of PEP. They found a significant reduction in rates of PEP (relative risk [RR] ¼ 0.51; 95% CI, 0.32-0.82), greater primary cannulation success (RR ¼ 1.07; 95% CI, 1.00-1.15), and less need for precut sphincterotomy (RR ¼ 0.75; 95% CI, 0.60-0.95) with guidewireassisted cannulation compared with the traditional contrast-assisted cannulation. In addition, there were no increases in other ERCP-related complications. This led to the conclusion that the guidewire-assisted cannulation technique seems to be the most appropriate first-line cannulation technique because it increases the primary cannulation rate and reduces the overall risk of PEP.
If initial cannulation attempts are unsuccessful or if the pancreatic duct is repeatedly cannulated, it is appropriate to consider switching to another method. Notably, the definition of difficult cannulation at present is an imperfect science with substantial variability among studies. The varying definitions of difficult cannulation have included failure to achieve biliary access after attempting to do so for longer than 10 minutes, 94 more than 5 unintentional pancreatic cannulations, 94 and 7 or more attempts required to ultimately achieve cannulation. 95 Pancreatic guidewire-assisted biliary cannulation is a technique that can be effectively used for biliary access, particularly if the pancreatic duct is repeatedly cannulated unintentionally and relatively easily. 96 A pancreatic guidewire is left in place in the pancreatic duct, which straightens the ampulla and acts as a barrier to prevent further pancreatic duct cannulation, and a second guidewire is passed through a papillotome, allowing for biliary cannulation alongside the existing pancreatic wire. Ito et al 97 investigated the frequency of PEP after pancreatic guidewire placement in achieving cannulation of the bile duct during ERCP. Pancreatic guidewire placement was performed in 113 patients where bile duct cannulation was found to be difficult (defined as unsuccessful cannulation within 15 minutes). Selective biliary cannulation with pancreatic guidewire placement was achieved in 72.6% of patients, with PEP occurring in 12.3%. Notably, prophylactic placement of a pancreatic stent (discussed in detail later herein) was attempted in 56.6% of patients (n¼64), of which only 3 (4.7%) developed mild pancreatitis. In contrast, of the 43.4% of patients (n¼49) without pancreatic stent placement, 11 (22.4%) developed mild pancreatitis. This led the authors to conclude that pancreatic guidewire placement is useful to achieve selective biliary cannulation and that subsequent pancreatic duct stenting can reduce the incidence of PEP. This role of prophylactic pancreatic duct placement in the setting of pancreatic THE SCOPE OF POST-ERCP PANCREATITIS guidewire placement is a current point of contention. Several experts believe that guidewire introduction into the pancreatic duct in and of itself is not responsible for increased rates of PEP despite data that found that manipulation of the pancreatic duct using a guidewire increased rates of PEP. 28, 98, 99 In addition, a recent prospective RCT by Ito et al 100 evaluated the prophylactic effect of pancreatic duct stenting on the frequency of PEP in patients who underwent pancreatic duct guidewire placement to achieve biliary cannulation. Seventy patients who underwent pancreatic duct guidewire placement to achieve selective biliary cannulation were randomized to receive a pancreatic duct stent (n¼35) or no stent (n¼35). The overall incidence of PEP was significantly lower in patients who received a pancreatic duct stent compared with those in the no-stent group (2.9% vs 22.9%, respectively), which led the authors to conclude that pancreatic duct stenting after pancreatic guidewire placement for selective biliary cannulation is recommended to reduce the incidence of PEP.
Precut sphincterotomy refers to a variety of endoscopic techniques, namely, needle-knife sphincterotomy, fistulostomy, or transpancreatic sphincterotomy or septomy, used to gain access into the bile duct when standard cannulation techniques have proved unsuccessful. Initial studies have found this technique to be an independent risk factor for the development of PEP, 30, 101 but it is more likely that the increased risk of PEP stems from the prolonged cannulation attempts with resultant papillary edema, stressing the importance of implementing alternative techniques earlier rather than later to reduce the incidence of PEP. This point is illustrated by a recent meta-analysis by Cennamo et al 102 that included 6 RCTs totaling 966 patients comparing cannulation and adverse event rates of early precut implementation with persistent attempts by conventional techniques. They found the rates of PEP to be 2.5% in patients randomized to early precut compared with 5.3% in patients from the persistent attempts cohort (OR¼0.47; 95% CI, 0.24-0.91). Several prospective trials, retrospective trials, and other meta-analyses have also reported that the use of precut sphincterotomy, when implemented early and successful, is not an independent risk factor for the development of PEP, [103] [104] [105] [106] and when performed by high-volume, qualified endoscopists can increase rates of primary cannulation and ultimately reduce the risk of PEP.
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Prophylactic Placement of Pancreatic Stents Pancreatic stents are thought to reduce the risk of PEP by preserving pancreatic drainage and relieving pancreatic ductal hypertension that might otherwise be impaired from papillary edema or spasm of the sphincter of Oddi, respectively. There have been several RCTs evaluating prophylactic pancreatic stent placement and the subsequent incidence of PEP (Table 4) . 100, It is important to be mindful of the disadvantages associated with prophylactic pancreatic stent placement. Placement of a pancreatic stent can be technically difficult and can incite further injury to the pancreatic orifice, resulting in an increased risk of PEP without any ductal decompression. 121, 122 In addition, given the fact that stent migration and duct perforation occur in approximately 4% of patients, 123 follow-up evaluation is required to ensure passage or removal of the stent, potentially subjecting the patient to an additional procedure. Last, the optimal duration for stent retention remains unknown, but one should be aware that prolonged retention has been found to induce ductal changes, which resemble those of chronic pancreatitis, although the long-term clinical significance of these changes remain unknown. 124 Despite the potential pitfalls, prophylactic stent placement is widely accepted as an effective means of preventing PEP 125, 126 and is recommended by consensus guidelines, in particular for high-risk patients. 53 Aggressive Intravenous Hydration Another point of contention is the use of aggressive intravenous fluid hydration in PEP prevention, which has long been the mainstay of treatment of acute pancreatitis irrespective of the underlying etiology. 37 A retrospective study by DiMagno et al, 127 which included 6505 patients who underwent 8264 ERCPs, investigated whether large periprocedural volumes influenced the severity of PEP. Of these patients, 211 developed PEP (48 mild, 141 moderate, and 22 severe), with available data for fluid volume for 173 patients with PEP. In a univariable and multivariable analysis, larger periprocedural fluid volume was found to be protective against moderate to severe PEP. A retrospective study by Sagi et al 128 looked to see whether there was any correlation between early intravenous volume infusion (defined as during the first 24 hours after ERCP) and length of PEP. The retrospective study included 72 patients, with the primary outcome being severity of PEP (defined as length of hospitalization according to consensus guidelines [ The choice of intravenous fluid is also important in PEP prevention. Mechanistically speaking, lactated Ringer solution closely resembles physiologic pH and, thus, may attenuate acidosis that promotes zymogen activation and resultant pancreatic inflammation as previously described. A recent pilot RCT by Buxbaum et al 129 determined whether aggressive periprocedural hydration with lactated Ringer solution reduced the incidence of PEP in 62 patients. Patients were randomly assigned (2:1) to receive aggressive hydration with lactated Ringer solution (3 mL/kg per hour during the procedure, 20-mL/kg bolus after the procedure, and 3 mL/kg per hour for 8 hours after the procedure; n¼39) or standard hydration with the same solution (1.5 mL/kg per hour during the procedure and for 8 hours after the procedure; n¼23). They found that none of the patients in the aggressive hydration group developed PEP, whereas 17% of patients in the standard hydration cohort developed PEP (P¼.02). There was no evidence of volume overload in these patients, suggesting that aggressive intravenous hydration with lactated Ringer solution can safely reduce the development of PEP.
CONSIDERATIONS FOR THE FUTURE OF PEP PREVENTION
Despite the advances in PEP prevention, there still are several questions that remain unanswered. Note that the large-scale, multicenter RCT by Elmunzer et al 49 underemphasized one key concept as outlined by Baron et al. 130 Elmunzer et al placed prophylactic pancreatic 131 investigated whether rectal indomethacin therapy could prevent PEP and any potential cost savings. They retrospectively classified participants from a previous large-scale, multicenter study 49 into 4 prevention groups: (1) those who received no prophylaxis, (2) those who had a prophylactic pancreatic duct stent placed, (3) those who received only rectal indomethacin, and (4) those who had a prophylactic pancreatic duct stent placed and received rectal indomethacin. Multivariate logistic regression and economic analysis comparing the costs associated with using rectal indomethacin alone, placing solely a prophylactic pancreatic duct stent, or the combination of both found that rectal indomethacin therapy alone seemed to be more effective in PEP prevention than the other strategies used. In addition, rectal indomethacin use alone was a cost-saving strategy that could save more than $150 million in the United States. This led the authors to conclude that there may be a role for the sole use of prophylactic rectal indomethacin in patients undergoing high-risk ERCP, which could also substantially reduce health care costs.
To date, there is no available data from largescale, multicenter RCTs directly comparing rectal NSAIDs with placement of a prophylactic pancreatic duct stent. A network meta-analysis by Akbar et al, 50 which totaled 29 studies (22 of pancreatic duct stents and 7 of NSAIDs), found that the use of rectal NSAIDs alone was superior to pancreatic duct stents alone in the prevention of PEP (OR¼0.48; 95% CI, 0.26-0.87). This led the authors to conclude that rectal NSAIDs are superior to prophylactic pancreatic duct stents alone in the prevention of PEP and should be considered first-line therapy in selected patients.
These data raise several key questions: (1) Should everyone receive rectal NSAIDs irrespective of patient-or procedure-related risk factors as outlined by the European Society of Gastrointestinal Endoscopy 53 or can we risk-stratify patients? Recent data from a prospective, double-blind RCT totaling 449 consecutive patients by Levenick et al 54 found that rectal indomethacin therapy does not universally prevent PEP. These data suggest that there may be a specific subset of patients who respond favorably to rectal indomethacin therapy, requiring further research. (2) In high-risk patients in whom biliary cannulation is immediately achieved, do we need to pursue pancreatic cannulation for stent placement or would rectal NSAID use be sufficient in PEP prevention? (3) Should we aggressively hydrate all patients with lactated Ringer solutions?
The Figure outlines a comprehensive approach and meaningful use of risk-stratification information and potential pharmacologic or procedural techniques that can be used to reduce the risk of PEP.
CONCLUSION
It is imperative for the clinical endoscopist to be cognizant of patient-and procedure-related risk factors to formulate a comprehensive risk reduction strategy to minimize the risk of PEP. Because patient-related risk factors cannot be modified, clinicians should analyze the risk:benefit ratio in each patient being considered for ERCP. Several questions remain unanswered regarding PEP prevention, in both the pharmacologic and procedural realms, that are currently under investigation.
Abbreviations and Acronyms: BISAP = bedside index for severity in acute pancreatitis; CBD = common bile duct; CT = computed tomography; ERCP = endoscopic retrograde cholangiopancreatography; Fr = French; NNT = number needed to treat; NSAID = nonsteroidal anti-inflammatory drug; OR = odds ratio; PEP = posteendoscopic retrograde cholangiopancreatography pancreatitis; RCT = randomized controlled trial; RR = relative risk; ULN = upper limit of normal Potential Competing Interests: Dr Baron is a consultant and speaker for Cook Endoscopy and Boston Scientific.
